Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish ...

The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial guidance, the company said. ・Genmab assumed sole responsibility for the ...

A new study reveals how a single cancer protein may simultaneously drive tumor survival and metabolic control, uncovering a ...

New clinical evidence indicates that a widely used supplement may alter gut microbes involved in vitamin D biology and ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit Looks Back at Pancreatic Cancer in 2025: A Year of Progress, Partnership, and Purpose.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs ...

With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. On the regional level, as the Human Development Index ...